Table 1

Patient cohort (n=13 618)

CovariatesLevelsOverall (13 618)Group
Surgery performed (n=4112)Recommended but refused (n=486)Not recommended (n=9020)P value
Age at diagnosis*61.2±14.4, 61 (51, 71)58.0±14.2, 58 (48, 67)67.3±14.4, 66.5 (58, 79)62.2±14.1, 62 (53, 72)<0.0001
Year of diagnosis20102086 (15.3%)765 (18.6%)114 (23.5%)1207 (13.4%)<0.0001
20112209 (16.2%)737 (17.9%)89 (18.3%)1383 (15.3%)
20122197 (16.1%)758 (18.4%)71 (14.6%)1368 (15.2%)
20132392 (17.6%)679 (16.5%)76 (15.6%)1637 (18.2%)
20142367 (17.4%)610 (14.8%)59 (12.1%)1698 (18.8%)
20152367 (17.4%)563 (13.7%)77 (15.8%)1727 (19.2%)
RaceWhite10 192 (74.8%)3056 (74.3%)371 (76.3%)6765 (75.0%)0.96
Black2323 (17.1%)699 (17.0%)74 (15.2%)1550 (17.2%)
Other race1049 (7.7%)349 (8.5%)40 (8.2%)660 (7.3%)
Unknown54 (0.4%)8 (0.2%)1 (0.2%)45 (0.5%)
T stageT0303 (2.2%)9 (0.2%)9 (1.9%)285 (3.2%)<0.0001
T11332 (9.8%)452 (11.0%)27 (5.6%)853 (9.5%)
T23731 (27.4%)1500 (36.5%)110 (22.6%)2121 (23.5%)
T32016 (14.8%)735 (17.9%)59 (12.1%)1222 (13.6%)
T44219 (31.0%)1276 (31.0%)162 (33.3%)2781 (30.8%)
TX2017 (14.8%)140 (3.4%)119 (24.5%)1758 (19.5%)
N stageN03070 (22.5%)678 (16.5%)136 (28.0%)2256 (25.0%)<0.0001
N15769 (42.4%)1565 (38.1%)184 (37.9%)4020 (44.6%)
N21453 (10.7%)777 (18.9%)47 (9.7%)629 (7.0%)
N31972 (14.5%)974 (23.7%)45 (9.3%)953 (10.6%)
NX1354 (9.9%)118 (2.9%)74 (15.2%)1162 (12.9%)
Metastasis siteDistant lymphnode mets only763 (5.6%)442 (10.8%)29 (6.0%)292 (3.2%)<0.0001
Bone only5136 (37.7%)1677 (40.8%)162 (33.3%)3297 (36.6%)<0.0001
Brain only194 (1.4%)57 (1.4%)4 (0.8%)133 (1.5%)0.008
Liver only966 (7.1%)381 (9.3%)28 (5.8%)557 (6.2%)<0.0001
Lung only1372 (10.1%)512 (12.5%)77 (15.8%)783 (8.7%)<0.0001
Bone+Liver1183 (8.7%)222 (5.4%)38 (7.8%)923 (10.2%)<0.0001
Bone+Lung1313 (9.6%)260 (6.3%)43 (8.9%)1010 (11.2%)<0.0001
Bone+Brain242 (1.8%)38 (0.9%)7 (1.4%)197 (2.2%)<0.0001
Brain+Liver31 (0.2%)3 (0.07%)2 (0.4%)26 (0.3%)0.02
Brain+Lung99 (0.7%)15 (0.4%)3 (0.6%)81 (0.9%)0.002
Liver+Lung355 (2.6%)85 (2.1%)15 (3.1%)255 (2.8%)0.09
Brain+Lung+Liver37 (0.3%)4 (0.1%)1 (0.2%)32 (0.4%)0.02
Bone+Lung+Liver744 (5.5%)96 (2.3%)40 (8.2%)608 (6.7%)<0.0001
Bone+Brain+Liver98 (0.7%)4 (0.1%)2 (0.4%)92 (1.0%)<0.0001
Bone+Brain+Lung151 (1.1%)25 (0.6%)6 (1.2%)120 (1.3%)0.53
Bone+Brain+Lung+Liver170 (1.3%)11 (0.3%)6 (1.2%)153 (1.7%)<0.0001
Number of Met sites*01527 (11.2%)722 (17.6%)52 (10.7%)753 (8.4%)<0.0001
17668 (56.3%)2627 (63.9%)271 (55.8%)4770 (52.9%)
23223 (23.7%)623 (15.2%)108 (22.2%)2492 (27.6%)
31030 (7.6%)129 (3.1%)49 (10.1%)852 (9.4%)
4170 (1.3%)11 (0.2%)6 (1.2%)153 (1.7%)
HER2/HR statusHR+/HER2−6912 (58.7%)2064 (53.4%)225 (61.8%)4623 (61.2%)<0.0001
HR+/HER2+2042 (17.3%)688 (17.8%)61 (16.8%)1293 (17.2%)
HR−/HER2+1123 (9.5%)411 (10.6%)32 (8.8%)680 (9.0%)
Triple negative1702 (14.5%)701 (18.1%)46 (12.6%)955 (12.7%)
HER2Negative8688 (70.9%)2771 (70.0%)272 (71.4%)5643 (71.3%)0.001
Positive3190 (26.0%)1101 (27.8%)96 (25.2%)1993 (25.2%)
Borderline376 (3.1%)86 (2.2%)13 (3.4%)277 (3.5%)
ERNegative3154 (25.0%)1211 (30.2%)87 (21.7%)1856 (22.7%)<0.0001
Positive9439 (74.9%)2803 (69.8%)312 (77.8%)6324 (77.2%)
Borderline11 (0.09%)2 (0.05%)2 (0.5%)7 (0.1%)
PRNegative4978 (39.9%)1758 (43.9%)146 (36.9%)3074 (38.1%)<0.0001
Positive7471 (59.9%)2245 (56.0%)247 (63.3%)4979 (61.7%)
Borderline28 (0.2%)5 (0.1%)3 (0.6%)20 (0.2%)
  • *Age at diagnosis was continuous varible and was compared by using ANOVA analysis among three local treatment subgroups.

  • †Number of met sites represented the number of metastatic lesions which existed at bone, liver, lung, brain or distant lymphnodes. This variable did not include the number of metastatic lesions at other distant sites.

  • ER, oestrogen receptor; PR, progesterone receptor.